Glow-in-the-dark animal captured on camera for first time
A photographer from Down Under has become the first person to capture a photo of a glowing marsupial in the wild.
Aussie photographer Ben Alldridge submitted a photo as part of the 2025 Beaker Street Science Photography Prize. The photo was of a wild Eastern quoll, which is carnivorous marsupial that's native to Tasmania and exhibits biofluorescence.
Using invisible ultraviolet light, Alldridge captured the mammal glowing in the dark, and his photo is considered the first photographic evidence of a quoll exhibiting biofluorescence in its natural habitat, people.com reported.
'Where their fur is normally fawn or black, under certain wavelengths of light, they exhibit a process referred to as biofluorescence — like nature's version of a white shirt glowing at a disco,' Alldridge said, per the Daily Mail.
Smithsonian Magazine reported that several mammals across the globe, many of them nocturnal, are known to exhibit this phenomenon, including polar bears, moles, zebras, wombats, armadillo and more. Non-mammals such as corals, insects, spiders, fish, amphibians, reptiles and birds also exhibit the phenomenon, although the exact biological purpose of biofluorescence is still unknown.
Alldridge said he hopes his photos and studies into biofluorescence will help solve the mystery surrounding it.
Recommended video
'I'd say it's likely a messaging or identifying system similar to our fingerprints, but that is wild speculation at best,' he said, per the Daily Mail. 'For now, we will just say they like to party.'
Alldridge's photography will be considered as part of the ongoing research.
'The amount of light we waste illuminating space — both physical and now literal — is ridiculous, and in many cases is counterproductive to why the lights are installed to begin with,' Alldridge said.
Alldridge's photo is one of 12 finalist images to be exhibited at the Tasmanian Museum and Art Gallery from Aug. 6-31, as part of the Beaker Street Festival.
Experts puzzled as chimps reportedly getting extra cheeky with grass fad
Pets can stave off dementia for people over 50 living alone: Study
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. 'Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,' said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. 'We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.' About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie Fields Precision AQ (Formerly Stern IR) E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – Twitter – Linked In – –


News24
3 hours ago
- News24
Humans beat AI at top maths contest
• For more financial news, go to the News24 Business front page. Humans beat generative AI models made by Google and OpenAI at a top international mathematics competition, despite the programmes reaching gold-level scores for the first time. Neither model scored full marks - unlike five young people at the International Mathematical Olympiad (IMO), a prestigious annual competition where participants must be under 20 years old. Google said Monday that an advanced version of its Gemini chatbot had solved five out of the six maths problems set at the IMO, held in Australia's Queensland this month. "We can confirm that Google DeepMind has reached the much-desired milestone, earning 35 out of a possible 42 points - a gold medal score," the US tech giant cited IMO president Gregor Dolinar as saying. "Their solutions were astonishing in many respects. IMO graders found them to be clear, precise and most of them easy to follow." Around 10 percent of human contestants won gold-level medals, and five received perfect scores of 42 points. US ChatGPT maker OpenAI said that its experimental reasoning model had scored a gold-level 35 points on the test. The result "achieved a longstanding grand challenge in AI" at "the world's most prestigious math competition", OpenAI researcher Alexander Wei wrote on social media. "We evaluated our models on the 2025 IMO problems under the same rules as human contestants," he said. "For each problem, three former IMO medalists independently graded the model's submitted proof." Google achieved a silver-medal score at last year's IMO in the British city of Bath, solving four of the six problems. That took two to three days of computation - far longer than this year, when its Gemini model solved the problems within the 4.5-hour time limit, it said. The IMO said tech companies had "privately tested closed-source AI models on this year's problems", the same ones faced by 641 competing students from 112 countries. "It is very exciting to see progress in the mathematical capabilities of AI models," said IMO president Dolinar. Contest organisers could not verify how much computing power had been used by the AI models or whether there had been human involvement, he cautioned.

Yahoo
4 hours ago
- Yahoo
Thought control: AI model transcribes thoughts from brainwaves
Imagine controlling your phone using only just thoughts. Connecting the human brain to computers represents the latest cutting-edge scientific advancement. Scientists at the University of Technology Sydney are exploring how artificial intelligence can interpret brain activity. Solve the daily Crossword